Skip to content

Janux Therapeutics JANX Ratios & Valuation

FY'25FY'24FY'23FY'22
Profitability
Operating margin-1,576.7%-643pp-933.6%-30.7pp-902.9%-124pp-779%+126pp
Net margin-1,136.3%-485pp-651.6%+69.6pp-721.2%+11.0pp-732.2%+166pp
Returns
Return on equity-11.5%-1.4pp-10.1%+7.4pp-17.5%+0.8pp-18.4%
Return on invested capital-20.5%0.0pp-20.5%+2.2pp-22.7%-1.2pp-21.5%
Efficiency
Asset turnover0.0×0.0×0.0×0.0×
Liquidity
Current ratio39×-20.2×59.2×+32.4×26.8×+6.7×20.1×-9.3×
Leverage
Debt-to-equity0.0×0.0×0.1×0.0×0.1×+0.1×
Per Share
Book value per share$15.44-18.9%$19.03+143%$7.82+1.1%$7.73-50.3%
Valuation
Market capitalization$892.81M-36.1%$3.14B+527%$500.92M-8.5%$547.66M-32.8%
Price / sales65×-84.6×296.5×+235×62×-1.6×63.6×-161×
Price / book0.9×-0.4×3.1×+1.6×1.5×-0.3×1.7×-0.5×

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where do Janux Therapeutics's ratios come from?
Every ratio is computed from Janux Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.